- Home
- CBZ vs PTGX Comparison
CBZ vs PTGX Comparison
Compare CBZ & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBZ
- PTGX
- Stock Information
- Founded
- CBZ 1987
- PTGX 2006
- Country
- CBZ United States
- PTGX United States
- Employees
- CBZ N/A
- PTGX N/A
- Industry
- CBZ Business Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CBZ Consumer Discretionary
- PTGX Health Care
- Exchange
- CBZ Nasdaq
- PTGX Nasdaq
- Market Cap
- CBZ 3.5B
- PTGX 3.7B
- IPO Year
- CBZ N/A
- PTGX 2016
- Fundamental
- Price
- CBZ $55.40
- PTGX $58.59
- Analyst Decision
- CBZ
- PTGX Strong Buy
- Analyst Count
- CBZ 0
- PTGX 9
- Target Price
- CBZ N/A
- PTGX $70.44
- AVG Volume (30 Days)
- CBZ 531.0K
- PTGX 906.1K
- Earning Date
- CBZ 10-28-2025
- PTGX 11-06-2025
- Dividend Yield
- CBZ N/A
- PTGX N/A
- EPS Growth
- CBZ N/A
- PTGX N/A
- EPS
- CBZ 1.84
- PTGX 0.80
- Revenue
- CBZ $2,420,673,000.00
- PTGX $209,180,000.00
- Revenue This Year
- CBZ $57.54
- PTGX N/A
- Revenue Next Year
- CBZ $5.95
- PTGX $185.11
- P/E Ratio
- CBZ $30.09
- PTGX $72.57
- Revenue Growth
- CBZ 46.49
- PTGX N/A
- 52 Week Low
- CBZ $53.92
- PTGX $33.31
- 52 Week High
- CBZ $90.13
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- CBZ 32.82
- PTGX 53.66
- Support Level
- CBZ $53.92
- PTGX $54.50
- Resistance Level
- CBZ $58.17
- PTGX $60.40
- Average True Range (ATR)
- CBZ 1.94
- PTGX 2.70
- MACD
- CBZ -0.51
- PTGX -0.14
- Stochastic Oscillator
- CBZ 12.03
- PTGX 55.35
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.